AbCellera Biologics Inc. Chief Financial Officer Andrew Booth filed a Form 4 on August 14, 2026, disclosing a purchase of 37,200 common shares of the company on that same date.

Key Highlights

  • Reporting person: Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc. (NASDAQ:ABCL)
  • Transaction: Purchase (Code P) of 37,200 common shares on 08/14/2026
  • Price paid: $10.32 per share
  • Direct beneficial ownership following transaction: 482,800 common shares
  • Indirect beneficial ownership: 130,959 common shares held by spouse
  • Filing date: August 14, 2026, signed by Tryn Stimart as attorney-in-fact

AbCellera CFO Share Purchase Details and Ownership Position

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Andrew Booth, the Chief Financial Officer of AbCellera Biologics Inc. (NASDAQ:ABCL), acquired 37,200 common shares on August 14, 2026, at a price of $10.32 per share. The transaction was recorded under transaction code "P," indicating an open-market purchase. The filing notes a "V" mark in the "V" column, which the form associates with transactions made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Following this transaction, the filing discloses that Booth directly beneficially owns 482,800 common shares. In addition, the filing reports 130,959 common shares held indirectly, with the nature of that indirect beneficial ownership described as "By spouse." No derivative securities transactions were reported in Table II of the filing.

The Form 4 was filed by one reporting person and signed on August 14, 2026, by Tryn Stimart, identified as attorney-in-fact for Booth. No amendment date is listed, indicating this is an original filing. AbCellera Biologics Inc. is listed on NASDAQ under the ticker symbol ABCL.

What Was Disclosed

The filing discloses a purchase of 37,200 AbCellera Biologics common shares at $10.32 per share by CFO Andrew Booth on August 14, 2026, resulting in direct beneficial ownership of 482,800 shares and indirect ownership of 130,959 shares through a spouse.